You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

~ Buy the DUAVEE (bazedoxifene acetate; estrogens, conjugated) Drug Profile, 2024 PDF Report in the Report Store ~

DUAVEE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Duavee, and when can generic versions of Duavee launch?

Duavee is a drug marketed by Wyeth Pharms and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-two patent family members in twenty countries.

The generic ingredient in DUAVEE is bazedoxifene acetate; estrogens, conjugated. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the bazedoxifene acetate; estrogens, conjugated profile page.

DrugPatentWatch® Generic Entry Outlook for Duavee

Duavee was eligible for patent challenges on October 13, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 10, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for DUAVEE?
  • What are the global sales for DUAVEE?
  • What is Average Wholesale Price for DUAVEE?
Summary for DUAVEE
International Patents:22
US Patents:2
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 2
Raw Ingredient (Bulk) Api Vendors: 1
Clinical Trials: 12
Patent Applications: 5
Drug Prices: Drug price information for DUAVEE
What excipients (inactive ingredients) are in DUAVEE?DUAVEE excipients list
DailyMed Link:DUAVEE at DailyMed
Drug patent expirations by year for DUAVEE
Drug Prices for DUAVEE

See drug prices for DUAVEE

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for DUAVEE
Generic Entry Date for DUAVEE*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for DUAVEE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
VA Office of Research and DevelopmentPhase 2
Penn State UniversityPhase 4
The John B. Pierce LaboratoryPhase 4

See all DUAVEE clinical trials

US Patents and Regulatory Information for DUAVEE

DUAVEE is protected by four US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of DUAVEE is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting DUAVEE

2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS

2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE

Crystalline polymorph of bazedoxifene acetate
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS

Crystalline polymorph of bazedoxifene acetate
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms DUAVEE bazedoxifene acetate; estrogens, conjugated TABLET;ORAL 022247-001 Oct 3, 2013 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Wyeth Pharms DUAVEE bazedoxifene acetate; estrogens, conjugated TABLET;ORAL 022247-001 Oct 3, 2013 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for DUAVEE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Pharms DUAVEE bazedoxifene acetate; estrogens, conjugated TABLET;ORAL 022247-001 Oct 3, 2013 ⤷  Sign Up ⤷  Sign Up
Wyeth Pharms DUAVEE bazedoxifene acetate; estrogens, conjugated TABLET;ORAL 022247-001 Oct 3, 2013 ⤷  Sign Up ⤷  Sign Up
Wyeth Pharms DUAVEE bazedoxifene acetate; estrogens, conjugated TABLET;ORAL 022247-001 Oct 3, 2013 ⤷  Sign Up ⤷  Sign Up
Wyeth Pharms DUAVEE bazedoxifene acetate; estrogens, conjugated TABLET;ORAL 022247-001 Oct 3, 2013 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for DUAVEE

See the table below for patents covering DUAVEE around the world.

Country Patent Number Title Estimated Expiration
Ecuador SP066911 POLIMORFO CRISTALINO DE UN ACETATO DE BAZEDOXIFENO ⤷  Sign Up
Luxembourg 91608 ⤷  Sign Up
Ukraine 85703 КРИСТАЛІЧНИЙ ПОЛІМОРФ БАЗЕДОКСИФЕНУ АЦЕТАТУ[КРИСТАЛЛИЧЕСКИЙ ПОЛИМОРФ БАЗЕДОКСИФЕНА АЦЕТАТА (CRYSTALLINE POLYMORPH OF BAZEDOXIFENE ACETATE) ⤷  Sign Up
Slovenia 802183 ⤷  Sign Up
South Korea 20060135866 CRYSTALLINE POLYMORPH OF A BAZEDOXIFENE ACETATE ⤷  Sign Up
European Patent Office 0802183 Composés oestrogènes (Estrogenic agents) ⤷  Sign Up
Norway 2009025 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for DUAVEE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0802183 SPC/GB09/045 United Kingdom ⤷  Sign Up PRODUCT NAME: BAZEDOXIFENE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/09/511/001 20090417; UK EU/1/09/511/002 20090417; UK EU/1/09/511/003 20090417; UK EU/1/09/511/004 20090417
0802183 PA2009007 Lithuania ⤷  Sign Up PRODUCT NAME: BAZEDOXIFENUM; REGISTRATION NO/DATE: EU/1/09/511/001 - EU/1/09/511/004 20090417
0802183 PA2009007,C0802183 Lithuania ⤷  Sign Up PRODUCT NAME: BAZEDOXIFENUM; REGISTRATION NO/DATE: EU/1/09/511/001 - EU/1/09/511/004 20090417
0802183 300416 Netherlands ⤷  Sign Up 300416, 20170415, EXPIRES: 20220414
0802183 364 Finland ⤷  Sign Up
0802183 91608 Luxembourg ⤷  Sign Up 91608, EXPIRES: 20220415
0802183 2009/028 Ireland ⤷  Sign Up PRODUCT NAME: BAZEDOXIFENE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/09/511/001-004 20090417
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.